Indication: Heart disease

Source: 3rd Annual International CoQ10 Conference, London, U.K.

Research: Italian scientists at the University of Ancona Hospital conducted a study that investigated biological endpoints such as functional capacity and ischemic threshold, in a randomized, placebo-controlled, crossover clinical trial. Twenty-one subjects with ischemic heart disease and heart failure were monitored for the effects of Q-Absorb 300 mg daily 100 mg t.i.d., exercise therapy and Q-Absorb plus exercise therapy versus placebo.
 
Results: Q-Absorb administration re­sulted in significant elevations in plasma CoQ10 averaging 3.7 mcg/mL plasma, peripheral arterial dilation and in­crease in peak VO2 (volume of oxygen consumed). The co-administration of Q-Absorb and exercise therapy resulted in the greatest gains, with endothelial dysfunction being almost normalized.